Harvard Business Review

JUNE 7, 2012

The numbers are enough to make the apple pop right out of the marketer's eye. Clearly that's not quite the target market for a new washer and dryer. for 2013, the fourth year in a row of relatively flat growth. PwC says four forces will continue to slow the rise in medical cost trend in 2013: 1. Scientific American).

Disruptive Innovation 11

Disruptive Innovation Innovation Pharmaceuticals Class 11

Harvard Business Review

NOVEMBER 27, 2013

Recent events have seen a rash of the departures from large corporates: Steve Ballmer from MicroSoft, Jeremy Levin from Teva Pharmaceutical, and Thorsten Heins from Blackberry. So it’s consistent with market forces. And a 2013 study by Xueming Luo, Vamsi K. Under her reign, on 1 November 2013, it closed at £1,498.00.

CEO 13

CEO Long-term Welch Pharmaceuticals 13

Harvard Business Review

JANUARY 13, 2014

But for 2013 he was only about 15 percent on target. But his 2013 forecasts were certainly within the realm of the possible; they just failed to materialize this year. But what happens when you want to look beyond today and examine your rivals or your market a few years from now? Obsessing over market leaders.

Uncertainty 8

Uncertainty Pharmaceuticals Industry Marketing 8

Harvard Business Review

MARCH 31, 2016

” In the article, a marketing expert explains why societal shifts would render the door-to-door salesman obsolete. In the late 20 th century, a proliferation of media options made buyers aware of products before talking to a salesperson, more so in B2C, but also in B2B markets.

B2B 8

B2B B2C Uncertainty Self-aware 8

Harvard Business Review

OCTOBER 23, 2012

(Commenters suggest the obvious – if you don’t know who’s calling, don’t pick up the phone, and eventually the robo-marketers will get the message.) The contest opens on October 25 at robocall.challenge.gov , and will run through January 17, 2013. EXCUSEZ-MOI, MADAME, BUT HOW DO YOU MANAGE TO LOOK SO CHIC?

Telemarketing 8

Telemarketing Pharmaceuticals Fashion Letter 8

Harvard Business Review

NOVEMBER 30, 2017

A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. But now the situation has reached such a tipping point that larger U.S. manufacturers are taking notice.

Supply Chain 8

Supply Chain McKinsey Incentives Bottom-up 8

Harvard Business Review

APRIL 3, 2017

The company was an eager user of my “cascading choices” framework for strategy that I have used for decades and written about extensively, most prominently in the 2013 book I wrote, with friend and colleague A.G. For example, Uber made a Where to Play choice that included China because it’s a huge and important market.

First-mover Advantage 14

First-mover Advantage Retail Strategy Pharmaceuticals 14

Harvard Business Review

DECEMBER 27, 2013

October 2013) The Dark Side of Generic Drugs Dirty Medicine Fortune Generic drugs can be inexpensive and effective alternatives to their branded counterparts. Sure, the company was eventually both punished and sold (it’s now one of the fastest-growing pharmaceutical businesses in the U.S.). And we all know what happened next.

Armstrong 8

Armstrong Long-term Short-term CEO 8

Harvard Business Review

MAY 5, 2016

But peruse some of the recent headlines about Iran , and you might wonder whether the market’s potential was overstated. However, despite a weakened economy, political tensions, market uncertainty, and the lingering effects of sanctions, Iran remains an important opportunity for multinationals in emerging markets.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

AUGUST 23, 2012

These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. Employees, particularly those in the sales and marketing functions, need to know the rules of the road," Langford says. The risks and penalties are real.

Compliance 15

Compliance Media Compliance Officer Policies 15

Harvard Business Review

MARCH 16, 2015

Please note that titles used here reflect the positions the individuals held in 2013, when we conducted the interviews for a separate article ). ” Staton identified the challenge of managing a global brand: “We had the McDonald’s brand, and in each country our market share and the product life cycle were in different stages.

CEO 8

CEO Stephenson Pharmaceuticals Globalization 8

Harvard Business Review

DECEMBER 21, 2015

Yet with all its foreign cash, Apple borrowed over $62 billion in 2013–2015 to do buybacks rather than repatriate its profits and pay U.S. Which brings us back to Pfizer, the pharmaceutical drug company that has provoked the new round of patriotic denunciations of corporate tax flight. Pfizer’s CEO, Ian C.

Hedge 8

Hedge Proposal Pharmaceuticals Price 8

Harvard Business Review

OCTOBER 21, 2013

I found myself reflecting on this recently while speaking with two business leaders in one of the world’s great pharmaceutical companies. How likely was it that they would be on top of the rapid developments in Asian consumer markets, or in technology and design emanating from Silicon Valley? It’s a tough challenge.

Drucker 8

Drucker Diversity Pharmaceuticals Uncertainty 8

Harvard Business Review

AUGUST 17, 2015

There was a spike in the 2000s when Venezuela began to provide petroleum at deeply discounted market prices, and that peaked just before the 2008-09 financial crisis. It is probably the best, most well-trained workforce at the cheapest labor-market price that any international investor could find anywhere in the world. In 2013 in U.S.

Biotechnology 8

Biotechnology Tourism Human Capital Pharmaceuticals 8

Harvard Business Review

OCTOBER 11, 2013

By 2013, we had honored Jack Dorsey of Twitter, Garrett Camp of Uber, famed choreographer Twyla Tharp, and Gangnam style pop artist Psy. Celine Schillinger sought to change the leadership landscape of Sanofi, a major pharmaceutical company. If you say we should, let’s do it.

Innovation 11

Innovation Christensen Decisionmaking CTO 11

Harvard Business Review

FEBRUARY 14, 2014

I’ve been watching the global economy for decades, and it seems to me that growth in the United States is about to speed up, while growth in the emerging markets is slowing down. Not only can natural gas be used as a feedstock for chemicals, fertilizers, pesticides, paints, plastics, and cosmetics, in 2013 the Cummins Corp.

Chemicals 8

Chemicals Pharmaceuticals Energy Creativity 8

Harvard Business Review

FEBRUARY 2, 2015

industries: 35 advanced manufacturing industries such as automotive and aerospace manufacturing, pharmaceuticals and semiconductors; three energy industries including electric power generation; and 12 service industries, from software design to telecommunications. average (20%) of highly intensive STEM occupations.

Industry 8

Industry McKinsey Engineering Innovation 8

Harvard Business Review

MARCH 6, 2014

His answer is that in a news market overflowing with facts, facts by themselves go unsold; they require a story—and that story, he says mischievously, needs some kind of bias on the part of the author, “a pair of lenses that slide over reality and aim to bring it more clearly into focus.” Where should all this go in our minds?”.

Peer Review 8

Peer Review Review Industry Wilde 8

Harvard Business Review

MAY 15, 2013

Beginning May 1, 2013, I facilitated a discussion around this question on LinkedIn. finance vs. marketing) and units (e.g. a fast-moving consumer products division vs. a pharmaceuticals division of a diversified firm). Nor can we develop good approaches to analyzing, preserving and transforming cultures.

Incentives 8

Incentives Definition Pharmaceuticals System 8

Harvard Business Review

JUNE 24, 2015

In a visionary setting, firms win by being the first to create a new market or to disrupt an existing one. Though the environment may look uncertain to others, visionary leaders see a clear opportunity for the creation of a new market segment or the disruption of an existing one, and they act to realize this possibility.

Strategy 8

Strategy Competitive Advantage Environment Execution 8